JP6387349B2 - 逆転写酵素阻害剤の結晶形態 - Google Patents

逆転写酵素阻害剤の結晶形態 Download PDF

Info

Publication number
JP6387349B2
JP6387349B2 JP2015534567A JP2015534567A JP6387349B2 JP 6387349 B2 JP6387349 B2 JP 6387349B2 JP 2015534567 A JP2015534567 A JP 2015534567A JP 2015534567 A JP2015534567 A JP 2015534567A JP 6387349 B2 JP6387349 B2 JP 6387349B2
Authority
JP
Japan
Prior art keywords
compound
batch
etoh
water
solid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015534567A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015531372A (ja
Inventor
マグワイヤー，コートニー，ケー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Publication of JP2015531372A publication Critical patent/JP2015531372A/ja
Application granted granted Critical
Publication of JP6387349B2 publication Critical patent/JP6387349B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2015534567A 2012-09-26 2013-09-20 逆転写酵素阻害剤の結晶形態 Active JP6387349B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261705780P 2012-09-26 2012-09-26
US61/705,780 2012-09-26
PCT/US2013/060787 WO2014052171A1 (en) 2012-09-26 2013-09-20 Crystalline form of a reverse transcriptase inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017170788A Division JP2018024683A (ja) 2012-09-26 2017-09-06 逆転写酵素阻害剤の結晶形態

Publications (2)

Publication Number Publication Date
JP2015531372A JP2015531372A (ja) 2015-11-02
JP6387349B2 true JP6387349B2 (ja) 2018-09-05

Family

ID=50388877

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015534567A Active JP6387349B2 (ja) 2012-09-26 2013-09-20 逆転写酵素阻害剤の結晶形態
JP2017170788A Pending JP2018024683A (ja) 2012-09-26 2017-09-06 逆転写酵素阻害剤の結晶形態

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017170788A Pending JP2018024683A (ja) 2012-09-26 2017-09-06 逆転写酵素阻害剤の結晶形態

Country Status (9)

Country Link
US (1) US9150539B2 (OSRAM)
EP (1) EP2900240B1 (OSRAM)
JP (2) JP6387349B2 (OSRAM)
CN (2) CN109384765A (OSRAM)
BR (1) BR112015005997A8 (OSRAM)
CA (1) CA2882947A1 (OSRAM)
ES (1) ES2773105T3 (OSRAM)
MX (1) MX362517B (OSRAM)
WO (1) WO2014052171A1 (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9598397B2 (en) 2013-12-04 2017-03-21 Merck Sharp & Dohme Corp. Process for making reverse transcriptase inhibitors
WO2018175271A1 (en) * 2017-03-24 2018-09-27 Merck Sharp & Dohme Corp. Formulation for parenteral administration
KR20220130698A (ko) * 2019-12-20 2022-09-27 에피자임, 인코포레이티드 Ezh2 억제제의 결정질 하이드로브로마이드 염, 이의 제조 및 암의 치료에 유용한 약학적 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7309700B2 (en) * 2004-04-02 2007-12-18 Boehringer Ingelheim International Gmbh Crystalline forms of 5,11-dihydro-11-ethyl-5-methyl-8-{2-{(1-oxido-4-quinolinyl)oxy}ethyl}-6H-dipyrido[3,2-b:2′,3′-e] [1,4]diazepin-6-one
CN1993332B (zh) * 2004-07-27 2011-04-06 弗·哈夫曼-拉罗切有限公司 作为非核苷逆转录酶抑制剂的苄基三唑酮化合物
JP5341881B2 (ja) * 2007-05-30 2013-11-13 エフ．ホフマン−ラ ロシュ アーゲー トリアゾロン類の製造方法
MX2010005483A (es) * 2007-11-20 2010-06-11 Merck Sharp & Dohme Inhibidores de transcriptasa inversa no nucleosidos.
HUE031785T2 (en) * 2010-03-30 2017-08-28 Merck Canada Inc Pharmaceutical composition comprising a non-nucleoside reverse transcriptase inhibitor
EP2558093A4 (en) * 2010-04-08 2013-10-02 Merck Sharp & Dohme PRODRUGS OF HIV INVERTER TRANSCRIPTASE INHIBITOR

Also Published As

Publication number Publication date
MX362517B (es) 2019-01-21
JP2015531372A (ja) 2015-11-02
WO2014052171A1 (en) 2014-04-03
BR112015005997A8 (pt) 2023-04-11
BR112015005997A2 (pt) 2017-07-04
CA2882947A1 (en) 2014-04-03
CN109384765A (zh) 2019-02-26
EP2900240B1 (en) 2020-01-08
ES2773105T3 (es) 2020-07-09
CN104684557A (zh) 2015-06-03
EP2900240A1 (en) 2015-08-05
EP2900240A4 (en) 2016-07-13
US20150232447A1 (en) 2015-08-20
JP2018024683A (ja) 2018-02-15
US9150539B2 (en) 2015-10-06
MX2015003767A (es) 2015-07-14

Similar Documents

Publication Publication Date Title
CN105209437B (zh) 心肌肌球蛋白激动剂的盐和制备盐的方法
AU2015330554B2 (en) Crystal form of bisulfate of JAK inhibitor and preparation method therefor
CN110678178B (zh) Mk2抑制剂的形式和组合物
EA031059B1 (ru) Кристаллическая форма альфа дималеата афатиниба
NO324495B1 (no) Polymorf form av 5-klor-3-(4-metansulfonylfenyl)-6'-metyl-[2,3']bipyridinyl, farmasoytisk preparat inneholdende denne, og anvendelse av forbindelsen for fremstilling av et medikament
JP2018024683A (ja) 逆転写酵素阻害剤の結晶形態
WO2018109786A1 (en) Novel polymoprphs and salts of polycyclic carbamoyl pyridone derivatives
JP5642766B2 (ja) アデフォビルジピボキシルの新規結晶形及びその製造方法
IL307295A (en) Solid forms of [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[5,4-D]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran -2-yl]propyl]acetate
KR20130004370A (ko) 아자비사이클로헥산의 신규한 다형체
JP2004530706A (ja) 純粋な結晶形態にある５−クロロ−３−（４−メタンスルホニルフェニル）−６’−メチル−［２，３’］ビピリジニル及び合成方法
WO2016172333A1 (en) A solid state form of perampanel
KR102013567B1 (ko) ６-(피페리딘-４-일옥시)-２ｈ-이소퀴놀린-１-온 하이드로클로라이드의 다형체
JP2024511296A (ja) ４ｈ－ピラン－４オンの構造を有するｃｙｐ１１ａ１阻害薬の固体形態
KR102013566B1 (ko) ６-(피페리딘-４-일옥시)-２ｈ-이소퀴놀린-１-온 하이드로클로라이드의 결정성 용매화물
WO2023134769A1 (zh) 4'-取代核苷的晶体、其制备方法、组合物和用途
WO2016009322A1 (en) Amorphous form and new crystalline forms of macitentan
HK1219484B (zh) 心肌肌球蛋白激动剂的盐和制备盐的方法
WO2011016044A1 (en) Novel polymorphs of adefovir dipivoxil
KR20020047301A (ko) 소듐2-(4,6-디메틸-피리미딘-2-일옥시)-3-(2-(3,4-디메톡시페닐)에톡시)-3,3-디페닐프로피오네이트 및 엔도텔린길항제로서의 그의 용도
HK1164640A (en) Polymorphs of darunavir

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150525

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160628

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160923

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161222

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180618

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180813

R150 Certificate of patent or registration of utility model

Ref document number: 6387349

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250